Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma [Yahoo! Finance]
Bausch + Lomb Corporation (BLCO)
Company Research
Source: Yahoo! Finance
ELIOS is an implant-free procedure that uses excimer laser technology for the treatment of glaucoma. Topline results will be discussed at 1:30 p.m. ET today on the inaugural Bausch + Lomb R&D Teach-in Webinar ( register here VAUGHAN, Ontario, March 23, 2026 BUSINESS WIRE )--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced positive 24-month results from the pivotal U.S. clinical trial of the ELIOS System. Developed for the treatment of elevated intraocular pressure (IOP) in patients with open angle glaucoma, ELIOS is an implant-free procedure that uses next generation excimer laser technology. The ELIOS procedure is currently CE marked in Europe and is under development and has not been reviewed by the FDA for safety and efficacy in the United States. "These strong U.S. study results reinforce everything we've learned about ELIOS during the years it has been available in Europe,
Show less
Read more
Impact Snapshot
Event Time:
BLCO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLCO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLCO alerts
High impacting Bausch + Lomb Corporation news events
Weekly update
A roundup of the hottest topics
BLCO
News
- A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript [Seeking Alpha]Seeking Alpha
- Ophthalmic Diagnostic Devices Market Size to Hit USD 5.22 Billion by 2035 Due to Growing Demand for Early Eye Disease Detection – SNS Insider [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of GlaucomaBusiness Wire
- Is It Time To Reconsider Bausch + Lomb (BLCO) After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
BLCO
Earnings
- 2/18/26 - Miss
BLCO
Sec Filings
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- BLCO's page on the SEC website